SARS-CoV-2 Spike Protein S1 (RBD):Fc (human) (rec.) (B.1.617.2.1 Variant,... Reference: AG-40B-0212 SARS-CoV-2 shares 79.5% sequence identity with SARS-CoV and is 96.2% identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. The coronaviral genome encodes four major structural proteins: the Spike (S) protein, Nucleocapsid (N) protein, Membrane/Matrix (M) protein and the Envelope (E) protein. The SARS Envelope (E) protein contains a short palindromic transmembrane helical hairpin that seems to deform lipid bilayers, which may explain its role in viral budding and virion envelope morphogenesis. The SARS Membrane/Matrix (M) protein is one of the major structural viral proteins. It is an integral membrane protein involved in the budding of the viral particles and interacts with SARS Spike (S) protein and the Nucleocapsid (N) protein. The N protein contains two domains, both of them bind the virus RNA genome via different mechanisms. The CoV Spike (S) protein assembles as trimer and plays the most important role in viral attachment, fusion and entry. It is composed of a short intracellular tail, a transmembrane anchor and a large ectodomain that consists of a receptor binding S1 subunit (RBD domain) and a membrane-fusing S2 subunit. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor angiotensin-converting enzyme 2 (ACE2) present at the surface of epithelial cells. Recently, a new variant of SARS-CoV-2, called B.1.617 was detected in India. Three sublineages have been found, B.1.617.1 (variant Kappa) and B.1.617.3 containing 4 mutations in the Spike protein with a double mutations in the Receptor Binding Region (L452R, E484Q) and B.1.617.2 (variant Delta) that is different since it contains the mutation T478K instead of E484Q. These variants (especially the B.1.617.1 & B.1.617.2) of the SARS-CoV-2 coronavirus have evolved as fast-growing variants outspacing other variants. Recently, a new variant derived from Delta (called Delta Plus and containing the mutations K417N, L452R & T478K) was detected in India and in several other countries. While studies are still underway, scientists say Delta Plus does not seem to be more transmissible than Delta.
Fc (human):FNDC4 (rec.) Reference: AG-40B-0213 Irisin is a recently described exercise-induced hormone secreted by skeletal muscle in mice and humans. Irisin activates beige fat cells (beige cells have a gene expression pattern distinct from either white or brown fat and are preferentially sensitive to the polypeptide hormone irisin). Irisin is cleaved from the type I membrane protein FNDC5 and improves systemic metabolism by increasing energy expenditure. FNDC4 is an ortholog of FNDC5 with 50% identity and 86% similarity compared to Irisin. FNDC4 as well as FNDC5 are extremely well conserved between species. The human FNDC4 gene is highly enriched in liver, brain tissue and adipocytes. FNDC4 is a factor with direct therapeutic potential in inflammatory bowel disease and possibly other inflammatory diseases. Recently, a new role of FNDC4 as a hepatokine has been published. Liver primarily controls the circulating levels of FNDC4 showing tight correlation with insulin sensitivity. In addition, a new orphan adhesion G protein-coupled receptor 116 (GPR116) has been identified as a receptor of FNDC4 in white adipose tissue (WAT), thereby establishing an endocrine FNDC4-GPR116 axis in the control of systemic glucose homeostasis. Moreover, the FNDC4-GPR116 axis is impaired in diabetic patients and therapeutic injections of recombinant Fc-FNDC4 into pre-diabetic mice corrected pre-diabetic hyperglycemia.
CD123 [IL-3Ralpha] (human)-muIg Fusion Protein (Biotin) Reference: ANC-545-030 Human CD123 (Interleukin-3 Receptor alpha) is a 70kDa type I transmembrane molecule, and is the low affinity receptor for the cytokine IL-3, which can stimulate proliferation or differentiation. When paired in a heterodimer with CD131 (IL-3Rbeta), it binds IL-3 with much higher affinity. CD123 is found on myeloid precusors, stem cells, a subset of T cells, some B cells, megakaryocytes, basophils, monocytes and epithelial cells. CD123 is present at high levels on many hematologic malignancies, and antibodies and CAR T cells against CD123 have been used successfully to combat acute myeloid leukemia (AML).
CD304 (human)-muIg Fusion Protein Reference: ANC-557-020 Human CD304 (neuropilin, NRP, NP1, BDCA-4) is a 140 kD type I glycoprotein expressed by a variety of tissue types,including Treg, follicular TH, neurons, dendritic cells and endothelial cells. Its ligands include VEGF165 and Semaphorin family members. It is a reliable marker for human BCP-ALL. Soluble CD304 has been used to slow progression of murine AML.
CD304 (human)-muIg Fusion Protein (preserviative free) Reference: ANC-557-820 Human CD304 (neuropilin, NRP, NP1, BDCA-4) is a 140 kD type I glycoprotein expressed by a variety of tissue types,including Treg, follicular TH, neurons, dendritic cells and endothelial cells. Its ligands include VEGF165 and Semaphorin family members. It is a reliable marker for human BCP-ALL. Soluble CD304 has been used to slow progression of murine AML.
Isthmin-1 (human) (rec.) (His) Reference: AG-40B-0214 Isthmin-1 (ISM1) was first identified as a gene expressed in the Xenopus midbrain hind brain organizer called isthmus, with a proposed role during early brain development. Isthmin-1 encodes a predicted ~50-kDa protein containing a signal peptide, a thrombospondin domain and an adhesion-associated domain. Isthmin-1 is important for embryonic and postnatal development. Growing evidence has shown that aberrant expression of Isthmin-1 can also affect the biological behavior of cancer. The Ism1 gene is conserved in mice and humans. A recent study showed that Ism1 is an adipokine that induces glucose uptake in human and mouse adipocytes. Ism1 is secreted by mature adipocytes and triggers a signaling cascade similar to that of insulin, regulating glucose uptake while suppressing lipid accumulation. Recombinant Isthmin-1 or overexpression of Ism1 causes a robust increase in GLUT4-dependent glucose uptake in cultured primary murine and immortalized human adipocytes as well as in primary human muscle cells and prevents insulin resistance and hepatic steatosis in a diet-induced obesity mouse model. Ablation of Isthmin-1 causes glucose intolerance and impaired insulin-stimulated adipocyte glucose uptake. Isthmin-1 suppresses de novo lipogenesis and increases protein synthesis in hepatocytes whereas Isthmin-1 knockdown in adipocytes reduces glucose uptake and insulin-dependent phosphorylation of protein kinase AKT at serine residue 473 (p-AKTSer473). Isthmin-1 signaling is dependent on PI3K and shares downstream phosphorylation targets with insulin signaling, such as p-AKTSer473, p-AKTThr308, p-ERK1/2Thr202/Tyr204 and p-S6Ser235/236. Isthmin-1 does not seem to act through the insulin receptor or the insulin-like growth factor 1 receptor; it is most likely to signal through another, yet to be identified, receptor tyrosine kinase.
Isthmin-1 (mouse) (rec.) (His) Reference: AG-40B-0215 Isthmin-1 (ISM1) was first identified as a gene expressed in the Xenopus midbrain hind brain organizer called isthmus, with a proposed role during early brain development. Isthmin-1 encodes a predicted ~50-kDa protein containing a signal peptide, a thrombospondin domain and an adhesion-associated domain. Isthmin-1 is important for embryonic and postnatal development. Growing evidence has shown that aberrant expression of Isthmin-1 can also affect the biological behavior of cancer. The Ism1 gene is conserved in mice and humans. A recent study showed that Ism1 is an adipokine that induces glucose uptake in human and mouse adipocytes. Ism1 is secreted by mature adipocytes and triggers a signaling cascade similar to that of insulin, regulating glucose uptake while suppressing lipid accumulation. Recombinant Isthmin-1 or overexpression of Ism1 causes a robust increase in GLUT4-dependent glucose uptake in cultured primary murine and immortalized human adipocytes as well as in primary human muscle cells and prevents insulin resistance and hepatic steatosis in a diet-induced obesity mouse model. Ablation of Isthmin-1 causes glucose intolerance and impaired insulin-stimulated adipocyte glucose uptake. Isthmin-1 suppresses de novo lipogenesis and increases protein synthesis in hepatocytes whereas Isthmin-1 knockdown in adipocytes reduces glucose uptake and insulin-dependent phosphorylation of protein kinase AKT at serine residue 473 (p-AKTSer473). Isthmin-1 signaling is dependent on PI3K and shares downstream phosphorylation targets with insulin signaling, such as p-AKTSer473, p-AKTThr308, p-ERK1/2Thr202/Tyr204 and p-S6Ser235/236. Isthmin-1 does not seem to act through the insulin receptor or the insulin-like growth factor 1 receptor; it is most likely to signal through another, yet to be identified, receptor tyrosine kinase.
TAPBPL (mouse):Fc (human) (rec.) Reference: AG-40B-0216 T cells play critical roles in the adaptive immune system, protecting the human body against cancer, bacterial, viral, fungal, and parasitic infections. T cell immune response is tightly controlled by immune checkpoint proteins that negatively or positively regulate T cell response. Among the immune checkpoint proteins, the B7 family plays a key role in controlling immune responses and belongs to the immunoglobulin (Ig) superfamily. A number of B7 family ligands have been identified, such as B7-1 (CD80), B7-2 (CD86), PD-L1 (B7-H1), PD-L2 (B7-DC), B7-H2 [inducible T cell co-stimulator ligand (ICOS)], B7-H3, B7-H4 (B7x, B7S1), B7-H5 (VISTA) and B7- H6. Because of the potential clinical applications of immune checkpoint proteins, there has been intense interest in identifying additional T-cell regulators. Recently, new antigen processing (TAP) binding protein-like (TAPBPL)/TAP binding protein-related (TAPBPR) molecule has been shown to share significant sequence similarity with some known B7 family members. TAPBPL protein is expressed on the surface of T cells, on antigen-presenting cells (APCs) including resting B cells, monocytes, macrophages, and DCs, as well as on some cancer cells including leukemia cells. TAPBPL behaves like other immune checkpoint proteins such as B7-H5 / VISTA or PD-L1 with a soluble recombinant version TAPBPL-Fc fusion protein that inhibits the proliferation and activation of CD4 and CD8 T cells in vitro and ameliorates autoimmune disease EAE in vivo. In contrast, treatment with anti-TAPBPL blocking antibody enhances antitumor immunity and inhibits tumor growth in vivo. Therefore, TAPBPL contains typical features of B7 family members, suggesting that it is a B7 family member or a B7 family-related molecule.
TAPBPL (human):Fc (human) (rec.) Reference: AG-40B-0217 T cells play critical roles in the adaptive immune system, protecting the human body against cancer, bacterial, viral, fungal and parasitic infections. T cell immune response is tightly controlled by immune checkpoint proteins that negatively or positively regulate T cell response. Among the immune checkpoint proteins, the B7 family plays a key role in controlling immune responses and belongs to the immunoglobulin (Ig) superfamily. A number of B7 family ligands have been identified, such as B7-1 (CD80), B7-2 (CD86), PD-L1 (B7-H1), PD-L2 (B7-DC), B7-H2 [inducible T cell co-stimulator ligand (ICOS)], B7-H3, B7-H4 (B7x, B7S1), B7-H5 (VISTA) and B7- H6. Because of the potential clinical applications of immune checkpoint proteins, there has been intense interest in identifying additional T-cell regulators. Recently, new antigen processing (TAP) binding protein-like (TAPBPL)/TAP binding protein-related (TAPBPR) molecule has been shown to share significant sequence similarity with some known B7 family members. TAPBPL protein is expressed on the surface of T cells, on antigen-presenting cells (APCs) including resting B cells, monocytes, macrophages, and DCs, as well as on some cancer cells including leukemia cells. TAPBPL behaves like other immune checkpoint proteins such as B7-H5 / VISTA or PD-L1 with a soluble recombinant version TAPBPL-Fc fusion protein that inhibits the proliferation and activation of CD4 and CD8 T cells in vitro and ameliorates autoimmune disease EAE in vivo. In contrast, treatment with anti-TAPBPL blocking antibody enhances antitumor immunity and inhibits tumor growth in vivo. Therefore, TAPBPL contains typical features of B7 family members, suggesting that it is a B7 family member or a B7 family-related molecule.
IL-2 Superkine (Fc) (H9T) Reference: AG-40B-0219 Interleukin-2 (IL-2) is a 133 amino acid glycoprotein with one intramolecular disulfide bond and variable glycosylation. It is secreted by activated T cells and induces proliferation and maturation of activated T cells, natural killer cells and lymphokine activated killer cells. IL-2 also stimulates proliferation of antibody-producing B cells, activates neutrophils and induces mononuclear cells to secrete IFN-gamma and TNF-alpha and -beta. Moreover, studies have shown that IL-2 is required for activation-induced apoptosis, an important homeostatic mechanism in the immune system, which is involved in the maintenance of peripheral tolerance to self-antigens. IL-2 promotes T cell proliferation and particularly naive T cells. IL-2 signaling on activated T cells is effected through a quaternary high-affinity receptor complex consisting of IL-2, IL-2Ralpha (CD25), IL-2Rbeta and IL-2Rgamma. Naive T cells are relatively insensitive to IL-2 as they only express small amounts of IL-2Rbeta and IL-2Rgamma. They only acquire sensitivity after CD25 expression, which captures the cytokine and presents it to the IL-2Rbeta and IL-2Rgamma receptors. IL-2 Superkine (Fc) is an artificial variant of IL-2 called H9, containing mutations at positions L80F / R81D / L85V / I 86V / I92F. These mutations are located in the molecule's core that acts to stabilize the structure and to give it a receptor-binding conformation mimicking native IL-2 bound to CD25. These mutations effectively eliminate the functional requirement of IL-2 for CD25 expression and elicit proliferation of T cells. Compared to IL-2, the IL-2 superkine induces superior expansion of cytotoxic T cells, leading to improved anti-tumor responses in vivo, and elicits proportionally less toxicity by lowering the expansion of T-regulatory cells and reducing pulmonary oedema. A new version of IL-2 Superkine with a new additional mutation called H9T reduces the binding of IL-2Rgamma and promotes the expansion of CD8+ T cells without driving terminal differentiation. TCR-transgenic and chimeric antigen receptor-modified CD8+ T cells that are expanded with H9T showed stronger anti-tumor activity in vivo in mouse models of melanoma and acute lymphoblastic leukemia. The new variant of IL-2 called H9T, helps to maintain activated CD8+ T cells in a stem-cell-like state, with greater anti-tumor activity in two mouse models. Like IL-2 Superkine (H9), IL-2 Superkine (H9T) should also work on human T cells.
SARS-CoV-2 Spike Protein S1 (RBD):Fc (human) (rec.) (B.1.1.529 Variant, Omicron) Reference: AG-40B-0220 SARS-CoV-2 shares 79.5% sequence identity with SARS-CoV and is 96.2% identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. The coronaviral genome encodes four major structural proteins: the Spike (S) protein, Nucleocapsid (N) protein, Membrane/Matrix (M) protein and the Envelope (E) protein. The SARS Envelope (E) protein contains a short palindromic transmembrane helical hairpin that seems to deform lipid bilayers, which may explain its role in viral budding and virion envelope morphogenesis. The SARS Membrane/Matrix (M) protein is one of the major structural viral proteins. It is an integral membrane protein involved in the budding of the viral particles and interacts with SARS Spike (S) protein and the Nucleocapsid (N) protein. The N protein contains two domains, both of them bind the virus RNA genome via different mechanisms. The CoV Spike (S) protein assembles as trimer and plays the most important role in viral attachment, fusion and entry. It is composed of a short intracellular tail, a transmembrane anchor and a large ectodomain that consists of a receptor binding S1 subunit (RBD domain) and a membrane-fusing S2 subunit. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor angiotensin-converting enzyme 2 (ACE2) present at the surface of epithelial cells. The B.1.1.529 variant, called Omicron was first reported to WHO from South Africa on 24 November 2021. Since then, B.1.1.529 has been detected globally. This variant seems to be at least equally infectious than B.1.617.2 (Delta), has already caused super spreader events and has outcompeted Delta within weeks in most countries. B.1.1.529 hosts an unprecedented number of mutations in its spike gene and early reports have provided evidence for extensive immune escape and reduced vaccine effectiveness.
GPX1 (human) (rec.) (His) Reference: AG-40A-0150Y Glutathione peroxidase 1 (GPX1) is an antioxidant enzyme that is down-regulated in cancer cells. Protects the hemoglobin in erythrocytes from oxidative breakdown. Its main role is the prevention of cancer initiation by ROS-mediated DNA damage.